- Home
- IFRX vs MAXN Comparison
IFRX vs MAXN Comparison
Compare IFRX & MAXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IFRX
- MAXN
- Stock Information
- Founded
- IFRX 2007
- MAXN 2019
- Country
- IFRX Germany
- MAXN Singapore
- Employees
- IFRX N/A
- MAXN N/A
- Industry
- IFRX Biotechnology: Pharmaceutical Preparations
- MAXN Semiconductors
- Sector
- IFRX Health Care
- MAXN Technology
- Exchange
- IFRX Nasdaq
- MAXN Nasdaq
- Market Cap
- IFRX 53.5M
- MAXN 56.0M
- IPO Year
- IFRX 2017
- MAXN N/A
- Fundamental
- Price
- IFRX $0.87
- MAXN $3.41
- Analyst Decision
- IFRX Strong Buy
- MAXN Sell
- Analyst Count
- IFRX 4
- MAXN 1
- Target Price
- IFRX $7.75
- MAXN $4.00
- AVG Volume (30 Days)
- IFRX 359.0K
- MAXN 200.9K
- Earning Date
- IFRX 08-07-2025
- MAXN 09-02-2025
- Dividend Yield
- IFRX N/A
- MAXN N/A
- EPS Growth
- IFRX N/A
- MAXN N/A
- EPS
- IFRX N/A
- MAXN N/A
- Revenue
- IFRX $140,242.00
- MAXN $509,048,000.00
- Revenue This Year
- IFRX N/A
- MAXN $100.37
- Revenue Next Year
- IFRX $1,276.37
- MAXN $24.61
- P/E Ratio
- IFRX N/A
- MAXN N/A
- Revenue Growth
- IFRX 30.90
- MAXN N/A
- 52 Week Low
- IFRX $0.71
- MAXN $2.49
- 52 Week High
- IFRX $2.82
- MAXN $27.43
- Technical
- Relative Strength Index (RSI)
- IFRX 45.31
- MAXN 51.83
- Support Level
- IFRX $0.82
- MAXN $3.20
- Resistance Level
- IFRX $0.93
- MAXN $3.51
- Average True Range (ATR)
- IFRX 0.06
- MAXN 0.31
- MACD
- IFRX 0.02
- MAXN -0.03
- Stochastic Oscillator
- IFRX 33.94
- MAXN 35.05
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
About MAXN Maxeon Solar Technologies Ltd.
Maxeon Solar Technologies Ltd is engaged in the manufacturing and marketing of premium solar technology. It owns and operates solar cell and panel manufacturing facilities located in Malaysia, Mexico, and the Philippines. The company's primary products are the Maxeon line of interdigitated back contact (IBC) solar cells and panels, and the Performance line (formerly, P-Series) of shingled solar cells and panels. the Maxeon line of solar panels are the highest-efficiency solar panels on the market with an aesthetically pleasing design, and the Performance line of solar panels offers a high-value and cost-effective solution. It is targeted at residential and small-scale commercial customers across the globe. The company derives its revenue from the United States, France, Italy, and others.